Larimar Therapeutics (LRMR) Enterprise Value (2016 - 2020)
Historic Enterprise Value for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to -$102.3 million.
- Larimar Therapeutics' Enterprise Value fell 2475.79% to -$102.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$102.3 million, marking a year-over-year decrease of 2475.79%. This contributed to the annual value of -$44.1 million for FY2019, which is 6268.27% up from last year.
- Larimar Therapeutics' Enterprise Value amounted to -$102.3 million in Q3 2020, which was down 2475.79% from -$113.7 million recorded in Q2 2020.
- Larimar Therapeutics' 5-year Enterprise Value high stood at -$44.1 million for Q4 2019, and its period low was -$166.2 million during Q1 2016.
- Moreover, its 5-year median value for Enterprise Value was -$104.7 million (2019), whereas its average is -$106.1 million.
- Its Enterprise Value has fluctuated over the past 5 years, first crashed by 8004.38% in 2016, then surged by 6268.27% in 2019.
- Quarter analysis of 5 years shows Larimar Therapeutics' Enterprise Value stood at -$129.2 million in 2016, then grew by 21.01% to -$102.1 million in 2017, then fell by 15.69% to -$118.1 million in 2018, then skyrocketed by 62.68% to -$44.1 million in 2019, then crashed by 132.21% to -$102.3 million in 2020.
- Its Enterprise Value stands at -$102.3 million for Q3 2020, versus -$113.7 million for Q2 2020 and -$63.9 million for Q1 2020.